重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗难治性类风湿关节炎的临床疗效观察  

The curative effect of refractory or resistant rheumatoid arthritis(RRA) with recombinant human tumor necrosis factor(rhTNFR:Fc) protein

作　　者：陈美玲[1] 谭志明[1] 邹世勇[1] 黄志勇[1] 

机构地区：[1]广东省惠州市中心人民医院,广东惠州516001

出　　处：《中国医药导报》2008年第23期73-74,共2页China Medical Herald

摘　　要：目的:探讨重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(rhTNFR:Fc)治疗难治性类风湿关节炎的临床疗效。方法:50例难治性类风湿关节炎(refractory or resistant rheumatoid arthritis,RRA)随机分为治疗组25例和对照组25例。治疗组:益赛普25mg,皮下注射,每周2次,疗程6个月;对照组:安慰剂25mg,皮下注射,每周2次,疗程24周。疗效评价采用美国风湿病学会(ACR)疗效评定标准。结果:治疗组ACR20、ACR50、ACR70有效率均高于对照组(P<0.05),治疗组24周ACR20、ACR50、ACR70的有效率高于治疗组4周(P<0.05);治疗组发生不良事件6例(24.0%)高于对照组3例(12.0%)。结沦:rhTNFR:Fc治疗难治性类风湿关节炎有较好的疗效。Objective：To study curative effect of refractory or resistant rheumatoid arthritis（RRA） with a recombinant human tumor necrosis factor （rhTNFR：Fc） protein. Methods：50 cases of RRA were randomly divided into 25 cases of treatment group and 25 cases of the control group. The treatment group： 25 mg,subcutaneous injection,the second week,for 6 months; control group： placebo 25 mg,subcutaneous injection,the second week,the course of 24 weeks. Evaluation by the United States Institute of Rheumatology （ACR） criteria to be in effect. Results：The treatment group ACR20,ACR50,ACR70 efficiency were higher than the controls（P〈0.05）,the treatment group 24 weeks ACR20,ACR50,ACR70 efficient than the four-week treatment group（P〈0.05）; treatment group incidence of adverse events 6（24.0%）higher than three cases（12.0%）. Conclusion：rhTNFR：Fc treatment of RRA have a better effect.

关 键 词：肿瘤坏死因子类 重组融合蛋白质类 关节炎 类风湿 难治 疗效 

分 类 号：R593.22[医药卫生—内科学]